Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer

Recruiting now

Conditions studied: Rectal Cancer, Cancer of Rectum, Cancer of the Rectum, Neoplasms, Rectal, Rectal Tumors, Rectum Cancer, Rectum Neoplasms

In brief

Neoadjuvant therapy has been widely applied to locally advanced rectal cancer. However, about 50% of patients receiving this therapy do not respond well as evidenced by the fact that their T or N stages are not effectively decreased judged by postoperative pathological examination. The purpose of this trail is to identify the biomarkers (from within patients' tumor mass before neoadjuvant therapy) to predict resistance to neoadjuvant therapy. These biomarkers can help stratify neoadjuvant-resistant patients towards surgery while avoiding unnecessary chemoradio-based neoadjuvant therapy.

Key facts

Study ID
NCT03573791
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
People needed
152
Starts
2018-05-21
Expected to finish
2027-05-21
Last updated by the study team
2025-03-30

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.